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ObjectiveaaImproving quality of life is an important goal in the treatment of schizophrenia. In previous research, quality of life has 
been reported to be compromised in patients with schizophrenia. The aim of this study was to investigate whether quality of life may be 
impaired in first-episode schizophrenia patients and to identify the associated factors of quality of life in first-episode schizophrenia.
MethodsaaForty-eight patients with first-episode schizophrenia and 20 normal controls were recruited. Quality of life was measured by 
using the Quality of Life scale (QLS). General and social self-efficacy, perceived social support were measured by using the self-report 
scales. The clinical assessments and comprehensive neurocognitive battery were also administered.
ResultsaaFirst-episode group showed significantly decreased QLS total and QLS subscale scores compared to normal controls group. 
The key associated factors of quality of life in patients with first-episode schizophrenia were the negative symptoms and social self-efficacy.
ConclusionaaThis finding implies that compromised quality of life may be already emerged in schizophrenia in their first-episode and 
the psychosocial interventions should be targeting the negative symptoms and the psychosocial protective factors including self-efficacy in 
addition to simply ameliorating the positive symptoms to foster social reintegration and recovery of first-episode patients.
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INTRODUCTION
Impairment in quality of life is evident in patients with 
schizophrenia.
1,2 Psychiatric treatment for patients with 
schizophrenia should focus on enhancing patients’ quality of 
life and social integration in addition to simply ameliorating 
the positive symptoms.
3,4 Quality of life is a multidimensional 
construct encompassing not only the subjective domain of 
life-satisfaction,
5 but also the objective domains of functional 
capacity, psychological status, and social interactions.
3
Investigating schizophrenia-related determinants of objec-
tive quality of life is a pivotal step in elucidating influential fac-
tors associated with quality of life and in guiding the develop-
ment of future interventions designed to promote social integ-
ration.
6 The previous research examining quality of life among 
patients with schizophrenia has focused mainly on psychopa-
thology and neurocognition. Much of the previous work on 
quality of life among patients with schizophrenia has shown 
that the negative symptoms of disorder have a detrimental im-
pact on patients’ quality of life,
6 and this finding in also true for 
individuals experiencing first-episode schizophrenia.
7,8 How-
ever this relationship might be somewhat inflated as there is 
significant overlap between negative symptoms and quality of 
life.
9 The positive symptoms
10 have been reported to have 
minimal impact on quality of life. Neurocognitive impair-
ments have also been reported to be associated with poorer 
quality of life, especially with respect to level of functional ca-
pacity.
11,12 Two recent large-scale studies in chronic, multi-ep-202  Psychiatry Investig 2011;8:201-206
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isode schizophrenia patients conducted by different investiga-
tors (sample size=309
13 and 1,386
14) revealed that psycho-
pathology and neurocognitive function contribute indepen-
dently to quality of life among patients with schizophrenia, in 
spite of the negative symptoms were recalculated to avoid the 
redundancy of the overlapping between negative symptoms 
and functional aspects of quality of life.
9
Additionally, some psychosocial factors have been proposed 
to be protective factors that serve to optimize quality of life 
among patients with schizophrenia, and self-efficacy
15 has 
also been shown to be associated with Quality of life in schizo-
phrenia.
The aim of this study was to investigate whether quality of 
life may be impaired in first-episode schizophrenia patients 
and to identify the associated factors of quality of life in first-
episode schizophrenia. 
Based on the previous reports,
1,2,6,7,11,12,15 we hypothesized 
that 1) patients with first-episode schizophrenia may show 
compromised quality of life compared to normal controls, and 
that 2) quality of life might be associated with negative symp-
toms of schizophrenia, neurocognitive impairment, and psy-
chosocial protective factors, including self-efficacy and per-
ceived social support.
METHODS
Participants
The present study was part of the Green Program for Rec-
ognition and Prevention of Early Psychosis (GRAPE) project; 
the details of this project have been described elsewhere.
16-18 
Forty-eight individuals experiencing first-episode schizophre-
nia (31 inpatients) were recruited form Severance Hospital 
and Severance Mental Health Hospital of Yonsei University 
Health System between May 2007 and November 2010. The 
duration of psychotic illness was less than 36.0 months except 
one subject (74.0 months) (mean=10.5, SD=12.8, median=6.0 
months) following the onset of active psychotic symptoms for 
the first-episode schizophrenia group. All participants met the 
inclusion criteria of being between 15-35 years old. All schizo-
phrenia patients should be on their stable phase. And in the 
cases of inpatients, their hospital days were in the range of 3-6 
weeks. Participants were evaluated using the Structured Clini-
cal Interview for the DSM-IV.
19,20 The exclusion criteria were 
current or past neurological illness or traumatic brain injury 
for all participants; current or past psychiatric illness for the 
normal controls; and the number of psychiatric admission 
more than one or the duration of psychiatric medication more 
than 15 months for first-episode patients. There was no co-
morbid substance use disorder in first-episode patients. 
The present study was carried out in accordance with the 
Declaration of Helsinki. The Institutional Review Boards at 
Severance Hospital and Severance Mental Health hospital re-
viewed and approved this study. All participants gave written 
informed consent. 
Measures
The Heinrichs-Carpenter quality of life scale (QLS) was 
used to assess the quality of life. The QLS
21 is a 21-item semi-
structured interview used to assess the objective quality of life 
in patients with schizophrenia. This measure yields a total 
score and subscores for four domains: 1) intrapsychic founda-
tions (IF; e.g., motivation, curiosity, anhedonia), 2) interper-
sonal relations (IPR), 3) instrumental role (IR), and 4) com-
mon objects and activities (COA). The internal consistencies 
(alpha) of the total and subdomains score were each greater 
than 0.79 with the exception of COA (0.51) in the present 
study. 
Self-efficacy was assessed using the Self-efficacy Scale.
22 The 
Self-efficacy scale consists of two subscales: general self-effica-
cy, social self-efficacy.
22 Perceived social support was measured 
using the 30-item Interpersonal Support Evaluation List 
(ISEL),
23 which includes scales related to belonging, appraisal 
and information seeking, tangible support, and self-esteem 
support. The ISEL has been shown to have good psychomet-
ric properties among patients with severe psychiatric illness, 
including schizophrenia.
24 The internal consistencies (alpha) 
of the general and social self-efficacy of Self-efficacy Scale and 
the ISEL in the present study were found to be 0.93, 0.82 and 
0.92, respectively. The presence of psychopathology was eval-
uated using the Positive and Negative Syndrome Scale (PAN-
SS),
25 and the Hamilton Depressive (HAM-D)
26 and Hamil-
ton Anxiety (HAM-A)
27 scales. In present study, the modified 
negative syndrome of PANSS were recalculated by omitting 
three items, including emotional withdrawal, passive/apathet-
ic withdrawal, and difficulty in abstract thinking, which was 
suggested strategy to avoid the redundancy of common vari-
ance between the negative symptoms and QLS scores, by pre-
vious studies.
13,14 Neurocognitive function was assessed using 
a comprehensive battery that has been described in previous 
our work.
17 The scores of each of the assessment measures 
from the battery were converted to z-scores according to our 
previous larger study
17 and combined to create a composite 
global neurocognitive score. The comprehensive battery was 
composed of the 3-7 Continuous Performance Test,
28 visuo-
spatial and visuo-verbal 2-back test,
28 WAIS-digit span,
29 Rey 
Complex Figure Test,
30 Immediate and delayed recall scores, 
California Verbal Learning test (learning trials 1-5, short delay 
free recall, long delay free recall),
31 Wisconsin Card Sorting 
Test,
32 Stroop Test,
33 Controlled Oral Word Association Test,
34 
Figure Fluency Test,
35 and the Trail Making Test Part B.
36 The YY Song et al. 
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internal consistency of the global neurocognitive score in the 
present study was 0.90.
As some of the psychosocial scales and items from the com-
prehensive neurocognitive battery were not available prior to 
April 2008, some data of first-episode patients (for Self-effica-
cy, n=8; for ISEL, n=20; for HAM-D, n=1; for HAM-A, n=1 
and for neurocognitive battery, n=12) were not included in the 
statistical analysis. Some data from the neurocognitive battery 
were presented elsewhere in order to compare the neurocog-
nitive performance of first-episode groups
17 with another data 
of normal controls.
Procedures
The clinical interviews and assessments were administered 
by a psychiatrist within a week after recruitment into the study. 
Each participant received a packet of questionnaires, including 
the Self-efficacy Scale and Interpersonal Support Evaluation 
List. The neurocognitive batteries were administered within 2 
weeks of recruitment by a masters-level psychologist.
Statistical analysis
All rated scores had acceptable skewness and kurtosis statis-
tics (<1.0). The independent t-tests were done for clinical and 
socio-demographic variables. Pearson correlations were used 
to evaluate correlations between QLS scores and the psycho-
pathology, global neurocognitive function, the psychosocial 
scales. All variables significantly related to QLS total and sub-
domain scores were analyzed subsequently using a multiple 
linear regression to evaluate their independent contributions 
to quality of life. The regression model utilized a stepwise 
method. The missing data were subjected to pairwise dele-
tion. The criterion for significance was set at p<0.05.
RESULTS
Participant characteristics
Demographic and clinical characteristics of the normal con-
trols and first-episode schizophrenia group were presented in 
Table 1. There were no significant differences between two 
groups with respect to demographic characteristics. There 
were significant differences in the general and social self-effi-
cacy, perceived social support, positive, negative and general 
syndrome of PANSS, HAM-D and HAM-A scale, global neu-
rocognitive score between the two groups. 
Table 1. Clinical and demographic characteristics
Normal controls (N=20) FE schizophrenia (N=48)
Demographic characteristics
Sex: Male/Female 10/10   17/31
Job status: Student/Employed/Unemployed 9/5/6   22/7/19
Age (years) 24.1 (3.1)      23.7 (6.1)
Education level (years) 14.5 (1.5)      13.7 (2.2)
Self-rated psychosocial variables
General self-efficacy
a 46.8 (8.2)      36.3 (12.6)*
Social self-efficacy
a 13.9 (3.2)      11.3 (8.3)*
Perceived social support of ISEL
a 27.7 (2.8)      13.6 (8.3)*
Psychopathologies
Positive syndrome of PANSS  07.0 (0)      17.1 (6.0)*
Negative syndrome of PANSS 07.5 (1.1)      18.6 (6.8)*
Modified Negative syndrome of PANSS 04.2 (0.5)        9.8 (4.1)*
General psychopathology of PANSS   16.8 (2.3)      32.7 (9.4)*
Depressive symptoms of HAM-D
a 00.9 (1.2)        7.5 (6.8)*
Anxiety symptoms of HAM-A
a 01.0 (1.3)        7.7 (7.3)*
Neurocognition
a
Global neurocognitive score 0.18 (0.4)     -1.02 (0.7)*
Chlorpromazine equivalent dose 1,520.0 (354.5)
*p<0.05. 
aSome data of first-episode persons (for Self-efficacy, n=8; for ISEL, n=20; for HAM-D, n=1; for HAM_A, n=1 and for neurocogni-
tive battery, n=12) were not included in the statistical analysis. ISEL
23: Interpersonal Support Evaluation List, PANSS
25: Positive and Negative 
Syndrome Scale; Modified negative syndrome of PANSS were recalculated by omitting three items, including emotional withdrawal, passive/
apathetic withdrawal, and difficulty in abstract thinking, HAM-D: Hamilton Depressive Scale,
26 HAM-A: Hamilton Anxiety Scale
27; Chlor-
promazine equivalent doses was derived from Kroken et al.
39204  Psychiatry Investig 2011;8:201-206
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Comparison of quality of life between normal 
controls and first-episode patients
First-episode group showed significantly decreased QLS to-
tal, and across all subscale scores compared to normal controls 
group (Table 2).
Preliminary analyses in first-episode 
schizophrenia patients
The enhanced general self-efficacy, social self-efficacy per-
ceived social support, and neurocognitive performance were 
correlated to better QLS total and several subdomain scores. 
Increased severity of modified negative syndrome of PANSS 
was correlated to poorer QLS total and all subdomain scores 
(Table 3). Positive syndrome of PANSS, HAM-A and HAM-D 
were also related to poorer QLS total score and the scores of 
several subdomains. Outpatients (n=17) had better QLS score 
than inpatients (n=31) in the COA subdivision (p=0.008). 
There were no differences according to gender (p>0.36) or 
employment status (p>0.20). 
Multiple linear regression analyses 
in first-episode schizophrenia patients
The modified negative syndrome and social self-efficacy 
were significant associated factors of QLS total. Modified 
Negative syndrome was significantly related to the IF subdo-
main score and social self-efficacy was related to the IPR, IR, 
COA subdomain scores (Table 4). 
DISCUSSION
The main findings of this study were that the objective qual-
ity of life of individuals with first-episode patients group was 
poorer than normal controls group and the key associated fac-
tors of quality of life among individual with first-episode pa-
tients group were negative symptoms and social self-efficacy.
Patients with first-episode schizophrenia were found to 
have poorer quality of life and subdomains of quality of life 
such as intrapsychic foundation, interpersonal relations, in-
strumental role and common objects and activities and this is 
consistent with those of previous studies.
1,2 This finding means 
Table 2. Comparison of quality of life between normal controls 
and first-episode schizophrenia patients
Normal controls
(N=20)
FE schizophrenia
(N=48)
Total QLS 109.4 (8.9) 54.8 (22.3)*
Intrapsychic foundation 037.9 (3.5) 19.6 (8.7)*
Interpersonal relations 041.9 (4.5) 19.1 (9.7)*
Instrumental role 021.1 (2.2) 09.8 (6.0)*
Common objects and  
  activities
008.6 (0.9) 06.3 (2.2)*
*p<0.05. QLS
21: Heinrichs-Carpenter Quality of Life Scale
Table 3. Correlations of quality of life with psychosocial variables, psychopathologies, and neurocognitive function in first-episode patients
First episode schizophrenia (N=48)
Total IF IPR IR COA
Demographic variables
Education level (years) -0.20 -0.21 -0.11 -0.11 -0.32*
Duration of illness -0.19 -0.11 -0.18 -0.30* -0.07
Self-rated psychosocial variables
General self-efficacy
a -0.56** -0.48** -0.60** -0.27 -0.42**
Social self-efficacy
a -0.61** -0.53** -0.63** -0.33* -0.46**
Perceived social support of ISEL
a -0.45* -0.38* -0.55** -0.10 -0.36*
Psychopathology 
Positive syndrome of PANSS -0.30* -0.36* -0.23 -0.09 -0.32*
Modified Negative syndrome of PANSS -0.66** -0.67** -0.59** -0.32* -0.44**
Depressive symptoms of HAM-D
a -0.39** -0.35* -0.34* -0.31* -0.19
Anxiety symptoms of HAM-A
a -0.38** -0.39** -0.29* -0.28 -0.20
Neurocognitive function
a
Global neurocognitive function -0.36* -0.34* -0.35* -0.16 -0.34*
*p<0.05, **p<0.01. 
aSome data of first-episode persons (for Self-efficacy, n=8; for ISEL, n=20; for HAM-D, n=1; for HAM_A, n=1 and for 
neurocognitive battery, n=12) were not included in the statistical analysis. ISEL
23: Interpersonal Support Evaluation List, PANSS
25: Positive 
and Negative Syndrome Scale; Modified negative syndrome of PANSS were recalculated by omitting three items, including emotional with-
drawal, passive/apathetic withdrawal, and difficulty in abstract thinking, HAM-D
26: Hamilton Depressive Scale, HAM-A
27: Hamilton Anxiety 
Scale, IF: Intrapsychic Foundations, IPR: Interpersonal relations, IR: Instrumental role, COA: Common Objects and ActivitiesYY Song et al. 
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that compromised quality of life may be already present in 
schizophrenia patients in their first-episode. 
Negative symptoms were found to be independently con-
tributed to the decreased quality of life total and intrapsychic 
foundation subdomain in the first-episode patients group. In 
previous studies, this association was argued to partly reflect 
some redundancy of common variance between negative 
symptoms and quality of life for individuals experiencing 
schizophrenia.
7,8 In contrast, the present study found an asso-
ciation in spite of recalculation of negative symptoms accord-
ing to suggested strategy in previous studies
13,14 to avoid re-
dundancy. In line with previous reports,
6-8,13,14 quality of life 
was significantly associated with negative symptoms.
In addition to negative symptoms, social self-efficacy was 
also independent contributing factor of better quality of life 
total and across all subdomins in first-episode patients. As a 
human, intrinsic need such as esteem and self-actualization,
3 
may be unfulfilled due to presence of psychiatric illness, stig-
ma, and related factors. Thus, to promote quality of life, psy-
chosocial interventions should be developed to enhance self-
efficacy, especially social one through experience of personal 
mastery in addition to the reduction of the negative symp-
toms.
Contrary to our hypothesis, global neurocognitive function 
and perceived social support were not independent factors of 
quality of life in first-episode schizophrenia patients. In regard 
of global neurocognitive function, first, there may be only a 
modest relationship, which may have gone undetected due to 
the small sample size of this study. Second, neurocognitive 
function may not translate into real-world function due to the 
influence of psychopathology, lack of opportunity, or other 
factors, which was offered by Narvaez et al.
37 More plausibly, 
the impairment in neurocognitive function of this first-epi-
sode groups were only 1.0 standard deviation (SD) below the 
performance of normal controls, which may be not widely re-
lated to quality of life. Regarding of perceived social support, 
the lack of independent contribution to quality of life may be 
due to that the considerable data (20 of 48) ISEL was not in-
cluded in statistical analysis.
In regard of affective psychopathology in present study, de-
pression and anxiety was not independent contributing factor 
of objective quality of life in first-episode schizophrenia pa-
tients, although there were significant correlations between 
QLS and HAM-D, and HAM-A. It may be explained that the 
affective symptoms in schizophrenia may be nonspecific 
symptoms since these depression and anxiety symptoms were 
found to be closely related with the positive (p<0.010) and 
negative symptoms (p<0.12) and self-efficacy (p<0.005).
The limitations of this study should be addressed. First one 
was the small sample sized and cross-sectional nature, which 
precludes conclusions regarding causality. In addition, some 
data including ISEL and global neurocognitive function were 
not included into statistical analysis. In the near future, longi-
tudinal follow-up studies with larger samples with full data set 
will be needed to elucidate the key determinants of quality of 
life among individuals with first-episode schizophrenia. Sec-
ond, in present study, there was no measurement of subjective 
quality of life. It was reported that in schizophrenia patients, 
the subjective rating of quality of life may be valid and infor-
mative on the point of life satisfaction.
38 Hence, future study 
aiming to further explore this issue of determinants of subjec-
tive and objective quality of life will be needed in the first-epi-
sode schizophrenia patients. Finally, other variables such as 
level of insight, and side effect of antipsychotic medications 
were not included in the present study, which may be con-
founding effects on the relationship.
38
In conclusion, the present study found that quality of life 
may be already compromised in schizophrenia patients in 
their early phase. More importantly, the key independent con-
tributing factors of objective quality of life may be negative 
Table 4. Stepwise multiple regression analyses of significant factors associated with quality of life in first-episode schizophrenia patients
Determinants
First episode schizophrenia (N=48)
β
a t p ΔR
2b R
2c F df p
Total Modified Negative syndrome -0.46 -2.70 0.013 0.43 0.48 12.59 2, 23 <0.001
Social self-efficacy
d 0.36 2.07 0.050 0.09
IF Modified Negative syndrome -0.67 -4.47 <0.001 0.45 0.43 19.96 1, 24 <0.001
IPR Social self-efficacy
d 0.63 4.00 0.001 0.40 0.38 16.00 1, 24 0.001
IR Social self-efficacy
d 0.33 2.15 0.038 0.11 0.09 4.64 1, 37 0.038
COA Social self-efficacy
d 0.46 2.51 0.019 0.21 0.18 6.31 1, 24 0.019
All VIF <1.5, all condition index <10.1. 
aStandardized coefficient, 
bChanged variance, ΔR
2, 
cAdjusted R
2, Explained variance by model, 
dSome 
data of first-episode persons (for Self-efficacy, n=8 and for ISEL, n=20) were not included in the statistical analysis. IF: Intrapsychic Founda-
tions, IPR: Interpersonal Relations, IR: Instrumental Role, COA: Common Objects and Activities. Modified Negative syndrome: scores were 
recalculated by omitting three items, including emotional withdrawal, passive/apathetic withdrawal, and difficulty in abstract thinking of 
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symptoms and psychosocial protective factors of social self-
efficacy in individuals with first-episode schizophrenia. This 
finding implies that for social reintegration and recovery, psy-
chosocial interventions should be comprehensive, targeting 
negative symptoms and self-efficacy in addition to simply 
ameliorating the positive symptoms. 
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